TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05833893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPO1 inhibitor
Description: COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
Study: NCT04789642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood pressure measurement whatsapp educational program
Description: educational
Study: NCT05906134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural catheter
Description: The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local intercostal nerve block
Description: Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryo-analgesia and intercostal nerve block
Description: The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus plane catheter blocks and intercostal nerve blocks
Description: A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
Study: NCT04752579

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pilates exercise program
Description: The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Description: The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes.
Study: NCT06431763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: 300 mg s.c. administered at day 1 and day 90

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPA
Description: 180 mg daily per oral
Study: NCT05224869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo hydrogel rectal spacer placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT simulation
Description: CT simulation of radiation treatment planning 2-7 days after hydrogel placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: SBRT in 5 fractions over 1 week, 7 days after CT simulation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: one month after completing SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-implant dosimetry scan
Description: one month after brachytherapy
Study: NCT05578092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX0902
Description: SOS1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX0902
Description: SOS1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX0902
Description: SOS1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor
Study: NCT06193070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Play virtual misinformation escape room game

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Play virtual misinformation escape room game
Study: NCT05136755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study: NCT05663801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Bupivacaine in pectoral nerve block in mastectomy
Description: Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy
Description: Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy
Description: Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
Study: NCT04990583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face PrEP Adherence Intervention Based on LifeSteps
Description: This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face PrEP Adherence Intervention Based on LifeSteps
Description: This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Coaching Facilitated by Carium Adherence App
Description: The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
Study: NCT05578092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor
Study: NCT05645575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-label TMS
Description: Customized, Open-Label Transcranial Magnetic Stimulation
Study: NCT06247956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Description: SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Description: Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
Study: NCT05707975

Intervention type: OTHER
Intervention: Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents
Description: Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
Study: NCT03907982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
Study: NCT05369117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: indocyanine green labeled fluorescent laparoscopy
Description: indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: indocyanine green labeled fluorescent laparoscopy
Description: indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
Study: NCT06545214

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Video-EEG monitoring
Description: Video-EEG monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Video-EEG monitoring
Description: Video-EEG monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Respiratory monitoring and polysomnography
Description: heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Respiratory monitoring and polysomnography
Description: heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)
Study: NCT05728671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015
Description: Test drug
Study: NCT05596968

Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT06545214

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1 Hypercapnic challenge while participant is awake
Description: The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1 Hypercapnic challenge while participant is awake
Description: The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
Study: NCT05834803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal artery stenting
Description: Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Optimal medical therapy and sham treatment.
Study: NCT06545214

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2 Hypercapnic challenges while participant is sleeping
Description: In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2 Hypercapnic challenges while participant is sleeping
Description: In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auditory stimulus
Description: Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.
Study: NCT05550948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) - Mobile System
Description: The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) - Mobile System
Description: The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) - Mobile System
Description: The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Study: NCT04913961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supine Daoyin
Description: During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: western medicine conventional therapy
Description: The control group will get the western medicine conventional therapy with some additional tests for the study.
Study: NCT05288868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention: online didactic lecture and educational simulation activity
Description: The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief.